Merz signs cooperation deal with Grunenthal
Merz & Co of Germany has signed a worldwide cooperation agreement withGrunenthal GmbH on registration, development and marketing of novel glycine antagonists in the indication of pain. Merz notes that it has discovered and patented two new groups of substances (glycine antagonists and uncompetitive glutamate NMDA antagonists) for the treatment of serious central nervous system diseases.
With this cooperation, says Merz, Grunenthal, as a specialist in the field of pain therapy, has obtained worldwide and exclusive rights to further investigate selected glycine antagonists presently in preclinical research and further develop them "on an international level for all types of pain." Merz will continue its own R&D with the compounds in areas other than pain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze